Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MASS 
908 Devices Inc (MASS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: MASS (1-star) is a SELL. SELL since 2 days. Simulated Profits (4.89%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.77% | Avg. Invested days 18 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 286.16M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 4 | Beta 0.46 | 52 Weeks Range 1.81 - 9.34 | Updated Date 11/4/2025 |
52 Weeks Range 1.81 - 9.34 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.13% | Operating Margin (TTM) -64.2% |
Management Effectiveness
Return on Assets (TTM) -15.39% | Return on Equity (TTM) -53.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 201596857 | Price to Sales(TTM) 4.36 |
Enterprise Value 201596857 | Price to Sales(TTM) 4.36 | ||
Enterprise Value to Revenue 3.08 | Enterprise Value to EBITDA -3.15 | Shares Outstanding 36085698 | Shares Floating 22145071 |
Shares Outstanding 36085698 | Shares Floating 22145071 | ||
Percent Insiders 8.34 | Percent Institutions 82.95 |
Upturn AI SWOT
908 Devices Inc
Company Overview
History and Background
908 Devices Inc. was founded in 2012 and is headquartered in Boston, Massachusetts. It develops and commercializes purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis. The company's focus is on providing point-of-need solutions for applications in life sciences, forensics, and industrial markets.
Core Business Areas
- Handheld Devices: Development and sale of handheld mass spectrometry devices like MX908 for chemical threat detection and trace analysis.
- Desktop Devices: Development and sale of desktop mass spectrometry devices like ZipChip for biopharmaceutical and proteomics analysis.
- Consumables and Services: Providing consumables, software, and support services related to their devices.
Leadership and Structure
908 Devices is led by CEO Kevin J. Knopp. The organizational structure is typical of a technology company, with departments focused on R&D, sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- MX908: A handheld high-pressure mass spectrometer used for chemical threat detection, hazmat response, and narcotics identification. Competitors include Smiths Detection, Thermo Fisher Scientific, and Bruker. Market share data not publicly available but 908 Devices is a key player in the handheld mass spec space. Limited financial data available directly tied to this product's revenue.
- ZipChip: A microfluidics-based separation platform coupled with mass spectrometry for rapid analysis of biomolecules. Primarily used in biopharmaceutical and proteomics research. Competitors include Agilent Technologies, Waters Corporation, and SCIEX. Limited financial data available directly tied to this product's revenue. Market share data not publicly available.
Market Dynamics
Industry Overview
The analytical instrumentation market is driven by increasing demand for accurate and rapid analysis in various sectors like life sciences, environmental monitoring, and homeland security. The market is competitive, with established players and innovative startups.
Positioning
908 Devices is positioned as a provider of innovative, point-of-need mass spectrometry solutions. Their competitive advantage lies in the portability and ease of use of their devices, enabling analysis outside of traditional laboratory settings.
Total Addressable Market (TAM)
The total addressable market for mass spectrometry and related technologies is estimated to be in the billions of dollars annually. 908 Devices targets niche segments within this broader market, focusing on portable and rapid analysis solutions. The company has the potential to expand its market share by developing new applications and expanding its product line.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Portable and easy-to-use devices
- Strong brand reputation in niche markets
- Experienced management team
Weaknesses
- Limited scale compared to larger competitors
- Reliance on specific markets
- Relatively small product portfolio
Opportunities
- Expansion into new markets
- Development of new applications for existing products
- Strategic partnerships and acquisitions
- Increasing demand for point-of-need analysis
Threats
- Competition from larger, more established players
- Technological obsolescence
- Economic downturn
- Changes in regulatory environment
Competitors and Market Share
Key Competitors
- TMO
- WAT
- ABCB
Competitive Landscape
908 Devices competes with larger companies with greater resources. Its competitive advantage lies in its innovative, portable solutions and focus on niche markets.
Growth Trajectory and Initiatives
Historical Growth: 908 Devices has experienced growth in revenue driven by increased adoption of its products. However, growth rates have varied depending on market conditions and product launches.
Future Projections: Analyst estimates suggest continued revenue growth for 908 Devices driven by increasing demand for point-of-need analysis solutions.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts, developing new applications for existing products, and pursuing strategic partnerships.
Summary
908 Devices is a growing company with innovative technology in the portable mass spectrometry space. Their handheld devices offer a competitive advantage in point-of-need analysis. However, they face competition from larger, well-established players and need to continue to innovate and expand their market reach to sustain growth. Cash flow health will be key to watch out for as they compete with larger companies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 908 Devices Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-12-18 | Co-Founder, CEO, President & Director Dr. Kevin J. Knopp Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 246 | Website https://908devices.com |
Full time employees 246 | Website https://908devices.com | ||
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling. The company's products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.